{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:54:01Z","timestamp":1793987641721,"version":"4.8.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180886"],"award-info":[{"award-number":["U10CA180886"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180899"],"award-info":[{"award-number":["U10CA180899"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bogniard Family Neuro-Oncology Fund at Akron Children\u2019s Hospital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although survival outcomes for average-risk (AR) medulloblastoma remain excellent, patients experience significant long-term toxicities. To evaluate the effect of therapy dose modifications among children with AR medulloblastoma, we examined the association of cumulative chemotherapy dose with overall survival (OS) and event-free survival (EFS) for patients treated on Children\u2019s Oncology Group (COG) study ACNS0331.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort of children enrolled on ACNS0331 (medulloblastoma confirmed by methylation, received standard dose craniospinal radiation, and completed all cycles of chemotherapy) were evaluated for cumulative chemotherapy dose intensity continuously and categorically (\u226575% or &amp;lt;75% of planned dose). Cox proportional hazards regression models were used to examine associations of proportion of planned chemotherapy received with outcome. A secondary analysis separately evaluated each of the 4 molecular subgroups: Wnt-activated (WNT), Sonic Hedgehog Activated (SHH), group 3 and group 4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two hundred thirty-five children were followed for a median of 9.3 years (range, 7.0-10.4). Dose intensities of vincristine (VCR) and cisplatin showed the most variability (17% and 23.8% of patients received &amp;lt;75% of expected dosing, respectively). Molecular subgroup remained a significant predictor of outcome (EFS [P\u2009=\u2009.012] and OS [P\u2009=\u2009.008]). Cyclophosphamide and lomustine were not examined due to minimal dose variability. No significant differences in EFS or OS were found related to reduced dose intensity for VCR (P\u2009=\u2009.49 EFS, P\u2009=\u2009.52 OS) or cisplatin (P\u2009=\u2009.36 EFS, P\u2009=\u2009.35 OS) when analyzed independently. There was no difference in the effect of dose reductions by molecular subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Moderate dose reductions of at least 25% in VCR and cisplatin do not significantly affect survival in AR medulloblastoma. Effects of larger dose reductions (&amp;gt;50%) or dose reductions in high-risk disease were not studied.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag064","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:42:24Z","timestamp":1774356144000},"page":"1772-1780","source":"Crossref","is-referenced-by-count":2,"title":["Cumulative dose of chemotherapy and survival outcomes in children with average-risk medulloblastoma treated on Children\u2019s Oncology Group study ACNS0331"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5044-058X","authenticated-orcid":false,"given":"Erin","family":"Wright","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, Akron Children\u2019s Hospital , Akron, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2819-4946","authenticated-orcid":false,"given":"Catherine","family":"Billups","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, St. Jude Children\u2019s Research Hospital , Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3416-7031","authenticated-orcid":false,"given":"Sarah","family":"Rush","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Akron Children\u2019s Hospital , Akron, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7046-4316","authenticated-orcid":false,"given":"Yimei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, St. Jude Children\u2019s Research Hospital , Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Janns","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory School of Medicine , Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0563-3766","authenticated-orcid":false,"given":"Jeff M","family":"Michalski","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Washington University School of Medicine , St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-0616","authenticated-orcid":false,"given":"Ralph","family":"Salloum","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Boston Children\u2019s Hospital\/Dana Farber Cancer Institute , Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6623-3040","authenticated-orcid":false,"given":"Peter","family":"de Blank","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Cincinnati School of Medicine and Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2026070701513489600_noag064-B1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11060-017-2594-6","article-title":"Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013","volume":"135","author":"Khanna","year":"2017","journal-title":"J Neurooncol"},{"key":"2026070701513489600_noag064-B2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/0360-3016(95)02080-2","article-title":"Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma)","volume":"34","author":"Goldwein","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026070701513489600_noag064-B3","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.1999.17.7.2127","article-title":"Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children\u2019s Cancer Group Study","volume":"17","author":"Packer","year":"1999","journal-title":"J Clin Oncol"},{"key":"2026070701513489600_noag064-B4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1001\/archneur.65.11.1419","article-title":"Management of and prognosis with medulloblastoma: therapy at a crossroads","volume":"65","author":"Packer","year":"2008","journal-title":"Arch Neurol"},{"key":"2026070701513489600_noag064-B5","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1200\/JCO.2000.18.16.3004","article-title":"Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation","volume":"18","author":"Thomas","year":"2000","journal-title":"J Clin Oncol"},{"key":"2026070701513489600_noag064-B6","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-016-1569-6","article-title":"Risk stratification of childhood medulloblastoma in the molecular era: the current consensus","volume":"131","author":"Ramaswamy","year":"2016","journal-title":"Acta Neuropathol"},{"key":"2026070701513489600_noag064-B7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/(sici)1096-911x(199712)29:6&lt;563::aid-mpo8&gt;3.0.co;2-i","article-title":"Treatment of standard risk medulloblastoma with craniospinal irradiation, carboplatin, and vincristine","volume":"29","author":"Bergman","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"2026070701513489600_noag064-B8","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1200\/JCO.2013.50.9539","article-title":"Cytogenetic prognostication within medulloblastoma subgroups","volume":"32","author":"Shih","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026070701513489600_noag064-B9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/pbc.24670","article-title":"Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children\u2019s Oncology Group","volume":"61","author":"Nageswara Rao","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"2026070701513489600_noag064-B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071789","article-title":"Population pharmacokinetics of vincristine related to infusion duration and peripheral neuropathy in pediatric oncology patients","volume":"12","author":"van de Velde","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026070701513489600_noag064-B11","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2165\/00003495-200363150-00003","article-title":"Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management","volume":"63","author":"Verstappen","year":"2003","journal-title":"Drugs"},{"key":"2026070701513489600_noag064-B12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/pbc.21325","article-title":"Decrease in peripheral muscle strength and ankle dorsiflexion as long-term side effects of treatment for childhood cancer","volume":"50","author":"Hartman","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"2026070701513489600_noag064-B13","first-page":"2416","article-title":"Vincristine-induced peripheral neuropathy in pediatric cancer patients","volume":"6","author":"Mora","year":"2016","journal-title":"Am J Cancer Res"},{"key":"2026070701513489600_noag064-B14","doi-asserted-by":"publisher","first-page":"111079","DOI":"10.1016\/j.fct.2019.111079","article-title":"Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents","volume":"136","author":"Santos","year":"2020","journal-title":"Food Chem Toxicol"},{"key":"2026070701513489600_noag064-B15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/08880018.2019.1677832","article-title":"Vincristine-induced peripheral neurotoxicity: a prospective cohort","volume":"37","author":"Nama","year":"2020","journal-title":"Pediatr Hematol Oncol"},{"key":"2026070701513489600_noag064-B16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1177\/0883073813491829","article-title":"Vincristine-induced neuropathy in childhood ALL (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics","volume":"29","author":"Jain","year":"2014","journal-title":"J Child Neurol"},{"key":"2026070701513489600_noag064-B17","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-218981","article-title":"Severe vincristine-induced polyneuropathy in a teenager with anaplastic medulloblastoma and undiagnosed Charcot-Marie-Tooth disease","volume":"2017","author":"Aghajan","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2026070701513489600_noag064-B18","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.3747\/co.26.4491","article-title":"Treatment-induced remission of medulloblastoma using a chemotherapeutic regimen devoid of vincristine in a child with Charcot-Marie-Tooth disease","volume":"2","author":"Bernstock","year":"2019","journal-title":"Curr Oncol"},{"key":"2026070701513489600_noag064-B19","first-page":"179","article-title":"Acute neurotoxicity following vincristine due to Charcot-Marie-Tooth disease in a young child with medulloblastoma","volume":"6","author":"Kissoon","year":"2019","journal-title":"Neurooncol Pract"},{"key":"2026070701513489600_noag064-B20","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/cncr.10397","article-title":"Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration","volume":"94","author":"Kellie","year":"2002","journal-title":"Cancer"},{"key":"2026070701513489600_noag064-B21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ijc.29711","article-title":"Single agent carboplatin for pediatric low-grade glioma: a retrospective analysis shows equivalent efficacy to multiagent chemotherapy","volume":"138","author":"Dodgshun","year":"2016","journal-title":"Int J Cancer"},{"key":"2026070701513489600_noag064-B22","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.ejca.2009.01.015","article-title":"Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91","volume":"45","author":"Hoff","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026070701513489600_noag064-B23","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1200\/JCO.20.01372","article-title":"Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03)","volume":"39","author":"Gajjar","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070701513489600_noag064-B24","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1200\/JCO.20.02730","article-title":"Children\u2019s Oncology Group phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma","volume":"39","author":"Michalski","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070701513489600_noag064-B25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nrneurol.2012.78","article-title":"The clinical implications of medulloblastoma subgroups","volume":"8","author":"Northcott","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"2026070701513489600_noag064-B26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.76.4720","article-title":"Extensive molecular and clinical heterogeneity in patients with histologically diagnosed CNS-PNET treated as a single entity: a report from the Children\u2019s Oncology Group randomized ACNS0332 trial","volume":"36","author":"Hwang","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070701513489600_noag064-B27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/nop\/npaa039","article-title":"Late effects of cancer treatment: consequences for long-term brain cancer survivors","volume":"8","author":"Alemany","year":"2021","journal-title":"Neurooncol Pract"},{"key":"2026070701513489600_noag064-B28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-3565(24)37559-7","article-title":"First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate","volume":"286","author":"Neuwelt","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"2026070701513489600_noag064-B29","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1093\/neuonc\/noac126","article-title":"Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: a contemporary single-institution experience","volume":"24","author":"Saraf","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026070701513489600_noag064-B30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00520-024-08484-5","article-title":"Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes","volume":"32","author":"Li","year":"2024","journal-title":"Support Care Cancer"},{"key":"2026070701513489600_noag064-B31","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.critrevonc.2017.04.004","article-title":"Vincristine-induced peripheral neuropathy in children with cancer: a systematic review","volume":"114","author":"van de Velde","year":"2017","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag064\/67551096\/noag064.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/7\/1772\/67551096\/noag064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/7\/1772\/67551096\/noag064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:51:41Z","timestamp":1783403501000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/7\/1772\/8541714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,3,26]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag064","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,26]]}}}